APA (7th ed.) Citation

Lan, C., Lu, H., Zhou, L., Liao, K., Liu, J., Xie, Z., . . . Huang, X. (2024). Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study. Cancer Communications, 44(6), 654. https://doi.org/10.1002/cac2.12547

Chicago Style (17th ed.) Citation

Lan, Chunyan, et al. "Long‐term Survival Outcomes and Immune Checkpoint Inhibitor Retreatment in Patients with Advanced Cervical Cancer Treated with Camrelizumab Plus Apatinib in the Phase II CLAP Study." Cancer Communications 44, no. 6 (2024): 654. https://doi.org/10.1002/cac2.12547.

MLA (9th ed.) Citation

Lan, Chunyan, et al. "Long‐term Survival Outcomes and Immune Checkpoint Inhibitor Retreatment in Patients with Advanced Cervical Cancer Treated with Camrelizumab Plus Apatinib in the Phase II CLAP Study." Cancer Communications, vol. 44, no. 6, 2024, p. 654, https://doi.org/10.1002/cac2.12547.